Solutia Inc.’s Pharmaceutical Services Division (Solutia PSD) will construct a
facility for the synthesis of highly potent Active Pharmaceutical Ingredients (APIs). The new facility will be based at Solutia PSD’s existing site in Marly, Switzerland. The expansion will provide pharmaceutical companies with an important resource enabling the contract manufacture of highly potent drugs to be carried out to the highest standards of quality and efficiency. Commissioning of the new facility is planned for first quarter, 2003.
Oncology remains the largest area of unmet clinical need in pharmaceutical research, says Ed Robinson, president of Solutia PSD.
